Transcript Cervical Cancer in Malaysia

Cervical Cancer in
Malaysia
Mohamad Khairi bin Ghazali
Zakiyah Binti Karim
1. Introduction
 The burden of cervical cancer in Southeast Asia is moderately
high, where the costs of nationwide organized cytology
screening have been a significant limitation.
 The use of Pap testing for cytology-based screening has been
highly effective in preventing cervical cancer in industrialized
countries and will most likely be effective in countries where
screening is limited or nonexistent.
 Hence, the use of alternative screening modalities, such as
visual inspection of the cervix aided by acetic acid (VIA) with or
without magnification, is currently under evaluation.
 In addition, prophylactic human papilloma virus (HPV)
vaccination for the prevention of infection and related disease
is being considered as an additional cervical cancer control
strategy.
2. Burden of cervical cancer in
Malaysia
 Cervical cancer incidence and mortality
 Cervical cancer second most common cancer in Malaysia,
 Furthermore, it is the fourth most common cause of death in women
in Malaysia.
 In Southeast Asia, cervical cancer incidence (age-standardized rate
(ASR) 15.7 per 100,000) is similar for Indonesia and Malaysia.

Fig. 1 shows the ASR of cervical cancer in countries with existing cancer registries and the high variability within Malaysia
 In Malaysia, the overall incidence rate is 19.7 per 100,000 women,
however differs by ethnic group.
 Chinese women have the highest ASR of 28.8 per 100,000 women.
 Indians with 22.4 per 100,000 women.
 Malays (includes Peninsular Malaysia but not East Malaysia) with
10.5 per 100,000 women.
3. HPV prevalence in Malaysia
 HPV-16 and 18 are the two most common HPV types in
Southeast Asia, although HPV-18 alone is relatively more frequent
compared to the type distribution estimates in the rest of the world.
 The estimate for Malaysia is based on a small number of cases
(N = 23) and there was a high number of co-infections for HPV16 and 18, therefore, the interpretation of these data is limited.

Figure 2. Five most frequent HPV types in women with cervical cancer in Indonesia, Malaysia, the Philippines, and Thailand [10] and [11].
4. Risk factors for HPV infection
and cervical cancer in Malaysia
 The prevalence of cofactors - smoking, oral contraceptive use, and
fertility - for cervical carcinogenesis in Malaysia are shown below:
Cofactors
Current smoking (%
of women)
Malaysia 11.6
Ever use of oral
contraceptives (%)
Total fertility Rate
(per woman)
13.4
2.8
 In a cross-sectional school survey of 12–19 year old adolescents,
5.4% (of which 8.3% were males and 2.9% were females)
reported having had sexual intercourse.
 Median age at first sexual intercourse was 15 years; however,
this estimate may be underreported given that talking about sex is a
culturally taboo subject in Malaysia.
 However, an increasing proportion of adolescents are engaging
in premarital sex, which may reflect the rapid social changes in
the country and the increased likelihood of being exposed to
HPV and other sexually transmitted infections (STI).
5. Current cervical cancer screening
programs
 In 1969 screening program started using the Pap smear.
 In 1981 screening extended to include all family planning users.
 In 1995 various agencies, e.g.: the National Population and Family
Development Board (NPFDB), private clinics and hospitals,
university and army hospitals, and non-governmental organizations
like the Federation of Family Planning Association of Malaysia
(FFPAM) provided Pap smear services as part of a cancer campaign
where the Pap testing was available once every 3 years for all
females aged 20–65 years.
 According to the World Health Organization (WHO) Health
Surveys 2001/2002, Pap smear coverage was only 23%.
 The highest Pap smear uptake was among women aged 30–39
years (36.6%) compared to women in other age groups: 18–29
years (14.6%), 40–49 years (28.8%), 50–59 years (20.9%) and 60–
69 years (5%).
 The 2003 National Guidelines on Pap Smear Screening
recommended that all sexually active women aged 20–65 years
should attend screening annually for two consecutive years. If
both smears are normal, screening can continue every 3 years.
 In 2003, the Malaysian Ministry of Health (MoH)allocated
3.55 million MYR (~18 million CZK) for free Pap smear tests to
women attending public health facilities. The predominant
screening method is conventional cytology with only a few public
health services and the private sector offering liquid-based cytology.
 In 2005, public health facilities and government hospitals
contributed 69% of all Pap smear tests compared to private
health facilities, which contributed only 20.6%.
 From 1996 to 2005, the annual number of Pap tests ranged from
350,000 to 400,000 smears, with no significant variation in the total
number of tests over the years.
 Abnormal Pap smears and unsatisfactory ones for evaluation
accounted for 0.86% and 3.1%, respectively.
 The 1991 Bethesda reporting system is still in use and an effort to
review the 2004 Pap Smear Guide Book is underway.
 MoH has initiated a project to develop a centralized database
system for both public and private sectors to determine the
feasibility and cost-effectiveness of an organized screening
program to reduce the incidence of cervical cancer through a
call-recall system, and to develop a national Pap smear registry.
 This project also aims to increase Pap smear coverage to 75%
among women aged 20–65 years. The project is currently
undertaken in Klang, Selangor and in Mersing, Johor Baharu with
completion targeted for 2011.
 MoH has taken the initiative to also develop a National
Colposcopic Training program and to evaluate the role of VIA
and cryotherapy as modalities for secondary prevention. With
support from WHO, a demonstration project on VIA and cryotherapy
is in its early implementation phase in the low socioeconomic district
of Sik in the northern state of Peninsular Malaysia.
6. Cervical cancer prevention and
HPV vaccination
 The Malaysia Drug Authority approved the use of the
quadrivalent HPV vaccine (Gardasil®, Merck & Co., Inc.,
Whitehouse Station, NJ, USA) in October 2006
 Other studies on the prevalence of HPV and invasive cervical
cancer are also underway.
 A National Immunization Technical Committee under the Disease
Control Division of MoH has been given the responsibility to study
and make recommendations on the role of the HPV vaccine in
Malaysia.
 Currently, the MoH, non-governmental organizations (NGOs) and
pharmaceutical companies are actively involved in increasing
knowledge on HPV and cervical cancer using mass media, media
electronics, posters and pamphlets.
References
 Copyright © 2008 Elsevier Ltd All rights reserved. ICO Monograph Series on
HPV and Cervical Cancer: Asia Pacific Regional Report
 Epidemiology and Prevention of Cervical Cancer in Indonesia, Malaysia, the
Philippines, Thailand and Vietnam: Efren J. Domingoa, Rini Noviani, Mohd
Rushdan Md Noor, Corazon A. Ngelangel, Khunying K. Limpaphayom, Tran
Van Thuan, Karly S. Louie and Michael A. Quinn
 http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TD44TD5VXVD&_user=1490772&_coverDate=08%2F19%2F2008&_rdoc=1&_fmt=full&_
orig=search&_cdi=5188&_sort=d&_docanchor=&view=c&_searchStrId=110
9377138&_rerunOrigin=google&_acct=C000053052&_version=1&_urlVersi
on=0&_userid=1490772&md5=d2012b87d64e52f1e5cd5d4f7d5af4fd#secx5
 http://www.nst.com.my/articles/12cervic/Article/index_html
 http://www.springerlink.com/content/45m35887r0223341/